Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $10.0 million.

  • Janux Therapeutics' Gains from Investment Securities rose 537.74% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year decrease of 3016.49%. This contributed to the annual value of $8.9 million for FY2024, which is 1106.34% up from last year.
  • As of Q3 2025, Janux Therapeutics' Gains from Investment Securities stood at $10.0 million, which was up 537.74% from $10.2 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Gains from Investment Securities high stood at $23.5 million for Q4 2024, and its period low was -$1.1 million during Q2 2024.
  • For the 5-year period, Janux Therapeutics' Gains from Investment Securities averaged around $4.6 million, with its median value being $2.0 million (2021).
  • As far as peak fluctuations go, Janux Therapeutics' Gains from Investment Securities crashed by 538571.43% in 2022, and later surged by 831478.26% in 2024.
  • Janux Therapeutics' Gains from Investment Securities (Quarter) stood at $7000.0 in 2021, then skyrocketed by 4814.29% to $344000.0 in 2022, then decreased by 12.79% to $300000.0 in 2023, then skyrocketed by 7733.33% to $23.5 million in 2024, then tumbled by 57.64% to $10.0 million in 2025.
  • Its Gains from Investment Securities stands at $10.0 million for Q3 2025, versus $10.2 million for Q2 2025 and $3.0 million for Q1 2025.